Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
NCT06674343
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
144
Enrollment
OTHER
Sponsor class
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
DRUG:
Furmonertinib
Sponsor
Peking Union Medical College Hospital